Physician profile
Jimin Wang
NPI 1316933690
$8,732.24
in general payments reported to CMS, 2019-2025
29 companies · $2,018 in 2025
The $2,018 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,580 · 2020: $556 · 2021: $766 · 2022: $910 · 2023: $922 · 2024: $1,981 · 2025: $2,018.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,879 · Education: $41.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,878.94 |
| Education | $41.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,444.89 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Gilead Sciences, INC. | $1,439.35 | 2019-2025 | Livdelzi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $843.95 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $752.10 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $532.54 | 2024-2025 | |
| Amgen INC. | $476.91 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $474.99 | 2022-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $382.16 | 2019-2021 | |
| Celgene Corporation | $227.66 | 2019 | |
| Pfizer INC. | $161.37 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $156.93 | 2019-2022 | |
| Genentech USA, INC. | $138.70 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $130.15 | 2019 | |
| Janssen Biotech, INC. | $109.12 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $65.53 | 2023-2025 | Zoryve, Livalo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $55.05 | 2019-2020 | |
| Dexcom, INC. | $50.29 | 2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $48.64 | 2022-2023 | Xarelto |
| Glaxosmithkline, LLC. | $41.90 | 2024 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $26.68 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $22.92 | 2019 | |
| Viatris Specialty LLC | $22.57 | 2025 | Yupelri |
| Hikma Pharmaceuticals USA | $21.61 | 2021 | |
| Eyevance Pharmaceuticals LLC | $21.61 | 2021 | |
| Exact Sciences Corporation | $21.53 | 2025 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $18.84 | 2023 | Yupelri |
| Novartis Pharmaceuticals Corporation | $18.20 | 2022 | |
| Seqirus USA INC | $13.46 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Horizon Therapeutics Plc | $12.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jimin Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.